BiotechTube

Valbenazine Oral Capsule

ApprovedWithdrawn
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Tardive Dyskinesia

Conditions

Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities

Trial Timeline

Jan 1, 2025 → Feb 1, 2027

NCT ID
NCT06107829

About Valbenazine Oral Capsule

Valbenazine Oral Capsule is a approved stage product being developed by Neurocrine Biosciences for Tardive Dyskinesia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06107829. Target conditions include Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT06107829ApprovedWithdrawn
NCT05207085Phase 2Recruiting

Competing Products

13 competing products in Tardive Dyskinesia

See all competitors
ProductCompanyStageHype Score
SarizotanMerckPre-clinical
23
levetiracetam + placeboUCBPhase 3
74
ValbenazineNeurocrine BiosciencesPhase 1
30
NBI-98854 + NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
NBI-98854 + NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
NBI-98854Neurocrine BiosciencesPhase 3
74
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved
82
NBI-98854Neurocrine BiosciencesPhase 2
49
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 3
74
ValbenazineNeurocrine BiosciencesPhase 3
74
NBI-98854 + NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved
82
NBI-1065890 + PlaceboNeurocrine BiosciencesPhase 2
49

Other Products from Neurocrine Biosciences

ValbenazineApproved
82
ValbenazineApproved
82
Valbenazine + Placebo oral capsuleApproved
82
Valbenazine + Placebo oral capsuleApproved
82
NBI-1117568Phase 3
74